title: Advances in pharmacotherapy for pediatric anxiety disorders.
abstract: Pediatric anxiety disorders are prevalent, chronic, and often lead to significant impaired functioning that impacts both short- and long-term outcomes for children and adolescents. Treatment options include pharmacotherapy and psychosocial interventions. This presentation will review treatment advances specifically for pharmacotherapy. Current research supports serotonin reuptake inhibitors as the medication class to be the first-line treatment option for pediatric anxiety disorders. Available evidence for the efficacy of other classes of medications will be reviewed, along with the available approaches to manage partial responders and nonresponders. The risks and benefits of pharmacotherapy will also be reviewed. In addition, recent research has shown the potential promise of novel agents that act upon other neural systems implicated in the development of pediatric anxiety disorders. Novel compounds that affect the glutamate system will be discussed.
authors.affiliation: New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. RynnM@childpsych.columbia.edu
authors.forename: Moira
authors.initials: M
authors.lastname: Rynn
authors.forename: Anthony
authors.initials: A
authors.lastname: Puliafico
authors.forename: Charlotte
authors.initials: C
authors.lastname: Heleniak
authors.forename: Pranav
authors.initials: P
authors.lastname: Rikhi
authors.forename: Kareem
authors.initials: K
authors.lastname: Ghalib
authors.forename: Hilary
authors.initials: H
authors.lastname: Vidair
mesh_terms: D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001521:Behavior Therapy; D001921:Brain / Q000187:drug effects; D002648:Child; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D018698:Glutamic Acid; D017367:Selective Serotonin Reuptake Inhibitors